What Esco Aster does

Esco Aster Pte Ltd is a Singapore-based Contract Research, Development and Manufacturing Organization (CRDMO) that delivers end-to-end biopharmaceutical services spanning consultancy, drug discovery, process and CMC development, cGMP manufacturing, GLP toxicology, clinical trial material, aseptic fill-and-finish, stability testing, clinical development, and strategic capital fundraising support. The company serves pharmaceutical and biotechnology companies (its primary segment), animal health firms, cosmetics/cosmeceuticals brands, food and cellular agriculture companies, and healthcare and medical centers across ASEAN, East Asia, ANZ, South Asia, the UK, and the US.

The company's core differentiator is its proprietary Adherent Tide Motion® packed-bed adherent cell bioreactor platform, which enables linearly scalable manufacturing from 0.1L to 5,000L packed-bed volume (bioequivalent to 50,000L suspension). This platform is extended through adjacent technologies including 3D Tide Motion® (mimicking lung-like microenvironments for physiologically relevant cell behavior), Astericle™ (extracellular vesicle/exosome manufacturing), MiniTide® (3D dynamic culture for drug discovery and toxicology), Esco AsterMavors® (cellular agriculture and complementary proteins), continuous fermentation (liquid and solid-state), continuous flow chemistry for API synthesis, and perfusion-enabled Tide Motion® with integrated SMB/RMB chromatography. Production facilities in Singapore, Taiwan, Japan, China, South Korea, the UK, and the US operate under cGMP, GLP, AAALAC, ISO, and SFA certifications, with the SFA certification marking the world's first for a cultivated cell-based nutrition and meat facility.

Esco Aster operates a horizontally segmented, multi-modality business model combining fee-for-service project work, FTE-based collaborations, funded research, shared-risk co-development partnerships with IP licensing and royalties, inward licensing arrangements, and consultancy/strategic capital services. The company monetizes across modalities including viral and DNA vaccines, viral vectors (lentivirus, retrovirus, AAV), cell therapies (MSC, iPSC, CAR-T, including canine CAR-T), plasmid DNA, lipid nanoparticles, exosomes/extracellular vesicles, therapeutic peptides, monoclonal antibodies, APIs, cosmeceuticals (AsterCura™), and cultivated meat/seafood. It operates as an affiliate of Esco Lifesciences Group, which was founded in 1978 in Singapore and collectively employs approximately 1,700 staff across 42 locations in 25 countries; Esco Aster itself was established in 2015 as an intrapreneurial venture, spun out as a subsidiary in 2018, and completed its formal spin-off as an independent affiliate on 8 August 2022.

Name

Esco Aster

Legal name

Esco Aster Pte Ltd

Website

https://escoaster.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Esco Aster is a Singapore-based CRDMO offering end-to-end biopharmaceutical development and manufacturing services — from drug discovery and cGMP production to clinical and commercial scale — built on its proprietary Tide Motion® packed-bed bioreactor platform. It serves pharma, biotech, animal health, cosmeceuticals, and cellular agriculture clients across Asia, the UK, and the US.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing (CRDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Food Manufacturing (311)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG)

akta.pro secondary industries

Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG), Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing) (HLAMANAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Biopharmaceutical contract manufacturing
• Cell and gene therapy CDMO
• Viral vector production services
• Adherent bioreactor platforms
• Vaccine and exosome manufacturing

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services (CRDMO): Fee-for-service contract research, development, and manufacturing services spanning from early development through GLP tox, clinical trial material, and commercial production. Services include drug discovery, process development, cGMP manufacturing, testing, clinical development, and regulatory support.
2. Co-development Partnerships: Shared risk partnered co-development projects involving exclusive inward licensing of Background IP and ability to outward license/sub-license co-developed Foreground IP with subsequent royalties on sales.
3. Strategic Capital Fundraising Services: Fundraising as a service to align capital, capability, and execution for founders, startups, investors, and government research bodies.
4. Consultancy Services: Specialized biomanufacturing consultancy helping startups and biotech companies achieve critical fundraising and investment milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Esco Aster is a vertically integrated Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end services from early-stage consultancy and drug discovery through process development, cGMP manufacturing, testing, and clinical development, covering gene therapy, cell therapy, viral vector and plasmid DNA production, human and animal vaccines, extracellular vesicles (Astericle), therapeutic peptides, APIs, cosmeceuticals (AsterCura), and cellular agriculture (Esco AsterMavors). Its offerings are built around the proprietary Adherent Tide Motion® packed-bed bioreactor platform, which enables linearly scalable manufacturing from 0.1L to 5,000L packed-bed volume for adherent cell-based bioprocesses.

Product overview

Esco Aster is a vertically integrated Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end bioinnovation solutions from idea to exit. The company operates a platform-plus-services architecture built around its proprietary Adherent Tide Motion bioreactor technology. Core products span biopharmaceutical manufacturing including Gene Therapy, Cell Therapy, Viral Vector Production, Plasmid DNA Manufacturing, and Human Vaccines services. The company also offers Extracellular Vesicles (Astericle) and Exosome services for drug delivery, alongside Human Vaccines production. Supporting services include GLP Toxicology, Clinical Development, Aseptic Fill & Finish, Stability Testing, and Container Closure Integrity Testing. The platform includes continuous fermentation and flow chemistry capabilities, as well as specialized offerings in Cellular Agriculture (Esco AsterMavors), Cosmetics/Cosmeceuticals (AsterCura), and Therapeutic Peptides. Business support services include Consultancy, COGS & Techno-Economic Analysis, and Strategic Capital fundraising support.

Differentiator

Problem solved

Functional benefit

Brands

• Astericle™: Extracellular vesicle (EV) platform brand for partnering with cell and gene therapy businesses.
• AsterCura™
• Esco AsterMavors®

Products and services

• Gene Therapy CDMO Services

Quantifiable outcome

• High viral titers in range of 8 log10 achieved with Tide Motion® bioreactors for Vero-cell based vaccine production
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Shine-On BiomedicalcoreStrategic or Co-development Partner · 6 January 2026Esco Aster signed a clinical cGMP manufacturing contract with Shine-On Biomedical to support their HLA-G-targeted exosome drug delivery platform. Shine-On's lead product SOB100 received US FDA IND clearance in Q1 2025 and is undergoing Phase I clinical study, positioning it as potentially first-in-class HLA-G-targeted exosome platform. Esco Aster provides cGMP manufacturing and technical services for exosome loading feasibility studies, leveraging its 3D Tide Motion bioreactor technology for cost-efficient GMP manufacturing for Asia-Pacific innovators.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Pharmaron: China-headquartered CRDMO offering discovery, process development, and biologics/small-molecule manufacturing services. Comparable to Esco Aster as a vertically integrated CRDMO serving global biotech and pharma customers across modalities.
• FUJIFILM Diosynth Biotechnologies: CDMO specializing in biologics, viral vaccines, and gene therapy manufacturing. Directly comparable to Esco Aster across vaccine, gene therapy, and mammalian cell culture CDMO services, with broader global capacity.
• Hovione: Specialty CDMO with strong continuous flow chemistry, small-molecule API, and biologics capabilities. Comparable to Esco Aster in continuous flow chemistry, peptide manufacturing, and integrated drug substance/drug product services.
• AGC Biologics: Mid-to-large biologics CDMO offering mammalian and microbial production, gene therapy, and cell therapy services. Closely comparable to Esco Aster as a multi-modality biologics CDMO.
• Celonic Group: Europe-based biologics CDMO offering mammalian cell line development, GMP manufacturing, and aseptic fill-finish. Comparable to Esco Aster as a mid-sized, multi-modality biologics CDMO targeting biotech customers.
• Catalent: Global CDMO with biologics, cell therapy, and aseptic fill-finish capabilities. Comparable to Esco Aster across end-to-end biopharmaceutical development, manufacturing, and fill-finish services.
• WuXi Biologics: Leading Asia-based biologics CDMO with end-to-end discovery, development, and manufacturing services. Highly comparable to Esco Aster as a regional CRDMO competitor serving global biotech customers with cGMP biologics capacity.

Broad incumbents

• Thermo Fisher Scientific (Patheon CDMO): Diversified life-sciences giant whose Patheon/CDMO services business competes directly with Esco Aster in biologics, viral vectors, and clinical/commercial drug product manufacturing. Co-mentioned alongside Esco Aster as a leading player in the Singapore exosomes market.
• Lonza: World's largest contract biologics manufacturer offering mammalian cell culture, viral vector, and cell therapy CDMO services. Directly comparable to Esco Aster across biologics and cell/gene therapy manufacturing, though Lonza operates at materially larger scale with broader modality coverage.
• Samsung Biologics: Large-scale Korean CDMO with mega-plant biologics manufacturing capacity. Comparable to Esco Aster in serving biologics manufacturing demand from Asia-Pacific, though with a different scale and modality mix focused on mammalian bioreactor systems.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks2 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/esco-aster

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Esco Aster